Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI389 Monotherapy and in Combination with Sintilimab in Advanced Malignancies
NCT05164458Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI389 in solid tumor (advanced stage), pancreatic carcinoma and gastric adenocarcinoma (2 arms), sponsored by Innovent Biologics. Primary endpoints: Adverse Events and Serious Adverse Events up to 2 years and Dose-Limiting Toxicities at 28 days. Started Mar 2022; status: recruiting.
02
Drugs
IBI389
03
Conditions
solid tumor (advanced stage)pancreatic carcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NCT05164458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164458.